Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM 1032

Drug Profile

PM 1032

Alternative Names: anti-CLDN18.2 x 4-1BB biAb; CLDN18.2 x 4-1BB biAb; PM-1032

Latest Information Update: 09 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotheus
  • Developer Biotheus; Jikai Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Cancer

Most Recent Events

  • 08 Jul 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, First-line therapy) in China (IV) (NCT05839106)
  • 28 May 2022 PM 1032 is available for licensing as of 28 May 2022. https://www.biotheus.com/Business_Partnership.html
  • 08 Apr 2022 Pharmacodynamics and safety data from preclinical studies in Cancer were presented at 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top